We updated the design of this site on December 18, 2017. Learn more.
ClinicalTrials.gov
ClinicalTrials.gov Menu
IMPORTANT: Due to the lapse in government funding, the information on this web site may not be up to date, transactions submitted via the web site may not be processed, and the agency may not be able to respond to inquiries until appropriations are enacted. Updates regarding government operating status and resumption of normal operations can be found at opm.gov.

SEDPARK2: Post Marketing Surveillance to Observe Safety and Efficacy of Piribedil in Parkinson's Disease (PIR-002/K)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT00727727
Recruitment Status : Completed
First Posted : August 4, 2008
Last Update Posted : February 25, 2009
Sponsor:
Information provided by:

July 31, 2008
August 4, 2008
February 25, 2009
March 2008
December 2008   (Final data collection date for primary outcome measure)
to monitor use in daily routine practice including adverse events [ Time Frame: 3 months ]
to monitor use in daily routine practice including adverse events
Complete list of historical versions of study NCT00727727 on ClinicalTrials.gov Archive Site
to monitor use in daily routine practice including efficacy aspects [ Time Frame: 3 months ]
to monitor use in daily routine practice including efficacy aspects
Not Provided
Not Provided
 
SEDPARK2: Post Marketing Surveillance to Observe Safety and Efficacy of Piribedil in Parkinson's Disease (PIR-002/K)
Stabilization on, or Change-Over to the Non-Ergot Dopamine Agonist Piribedil in Patients With Morbus Parkinson - a Post Marketing Surveillance Study in Private Practices.
The objective of the Post Marketing Surveillance Study is to investigate the use of the non-ergot dopamine agonist piribedil (trade name: CLARIUM) in mono- and combination therapy in patients with Morbus Parkinson. Neurologists in private practices in Germany should document the safety and course of the disease/change of parkinsonian symptoms during stabilisation on, or change over from other dopamine agonist treatment under routine conditions. Piribedil should be prescribed according to its marketing authorisation.
Not Provided
Observational
Time Perspective: Prospective
Not Provided
Not Provided
Non-Probability Sample
Patients with Morbus Parkinson who require therapy with dopamine agonists
Parkinson's Disease
Drug: Piribedil
Parkinsonian patients
Intervention: Drug: Piribedil

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Completed
750
December 2008
December 2008   (Final data collection date for primary outcome measure)

Inclusion Criteria:

  • Male and female patients 18 years and older.
  • Indication: Morbus Parkinson.
  • Treatment with piribedil for the first time.
  • Monotherapy with piribedil.
  • Combination therapy with L-Dopa (from the beginning or secondary in combination with other antiparkinsonian drugs).

Exclusion Criteria:

Sexes Eligible for Study: All
18 Years and older   (Adult, Senior)
No
Contact information is only displayed when the study is recruiting subjects
Germany
 
 
NCT00727727
PIR-002/K
No
Not Provided
Not Provided
Dr. Martina Wangemann, Desitin Arzneimittel GmbH
Desitin Arzneimittel GmbH
Not Provided
Not Provided
Desitin Arzneimittel GmbH
February 2009